Biostem Technologies, Inc. (NASDAQ:BSEM – Get Free Report) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 119,203 shares, a decline of 78.5% from the August 15th total of 554,233 shares. Based on an average trading volume of 89,169 shares, the short-interest ratio is presently 1.3 days. Currently, 0.7% of the shares of the company are sold short.
Biostem Technologies Trading Up 3.1%
Shares of Biostem Technologies stock traded up $0.13 during mid-day trading on Friday, reaching $4.31. 142,954 shares of the stock were exchanged, compared to its average volume of 101,893. Biostem Technologies has a fifty-two week low of $2.25 and a fifty-two week high of $8.40. The company has a market cap of $76.93 million, a price-to-earnings ratio of -2.69 and a beta of 0.12. The firm has a 50-day simple moving average of $3.64 and a 200 day simple moving average of $4.46.
Wall Street Analyst Weigh In
BSEM has been the subject of a number of recent research reports. Wall Street Zen upgraded Biostem Technologies to a “sell” rating in a research note on Saturday, September 5th. Weiss Ratings assumed coverage on shares of Biostem Technologies in a research report on Wednesday, August 19th. They issued a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.
About Biostem Technologies
BioStem Technologies, Inc (NASDAQ: BSEM) is a biotechnology company focused on regenerative medicine and biologic tissue products. Through its operating businesses, the company develops, manufactures and distributes human tissue allografts intended to support wound care, surgical procedures and other regenerative applications.
Its product portfolio includes placental-tissue-based products, including amniotic membrane and related graft technologies. These products are designed for use by health-care professionals in applications such as wound management and tissue repair.
See Also
- Five stocks we like better than Biostem Technologies
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Biostem Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostem Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
